the quality, utility, and clarity of the information to be collected, and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Maria G. Button.

Director, Executive Secretariat. [FR Doc. 2023–00096 Filed 1–6–23; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Establishment of the Center for Forecasting and Outbreak Analytics

AGENCY: Centers for Disease Control and Prevention, HHS.

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC) has modified its structure. This notice announces the establishment of the Center for Forecasting and Outbreak Analytics.

DATES: This reorganization was approved by the Secretary of Health and Human Services on December 19, 2022, and became effective on January 4, 2023.

SUPPLEMENTARY INFORMATION: Part C

(Centers for Disease Control and Prevention) of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (45 FR 67772–76, dated October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as amended most recently at 87 FR 51670–51675, dated August 23, 2022) is amended to reflect the reorganization of the Office of the Director, Centers for Disease Control and Prevention.

Background: Establishing the Center for Forecasting and Outbreak Analytics is the result of the National Security Memorandum #1 (Section 5B) indicating the need to establish an interagency national Center and modernize global early warning and trigger systems to prevent, detect, respond to, and recover from emerging biological threats, as well as Section 2404 of the American Rescue Plan Act of 2021, Public Law 117-2, which provides funding in support of public health data surveillance and analytic infrastructure modernization initiatives at the Centers for Disease Control and Prevention. Specifically, the changes are as follows:

Under Part C, Section C–B, Organization and Functions, make the following change:

Center for Forecasting and Outbreak Analytics (CD)

The mission of the Center for Forecasting and Outbreak Analytics (CFA) is to advance U.S. forecasting, outbreak analytics, and surveillance capacities related to disease outbreaks, epidemics, and pandemics to support public health response and preparedness. To carry out its mission, CFA will: (1) forecast, model, and characterize the risks associated with outbreaks; (2) inform public health decision-makers and the public; (3) innovate public health solutions and capabilities related to forecasting, surveillance, and analytics; (4) accelerate access to and use of data for public health decision-makers to mitigate the effects of disease threats; and (5) serves as a hub for research and development for public health analytics and modeling.

Office of the Director (CD1)

(1) Provides strategic direction regarding forecasting, surveillance, and data analytics; (2) coordinates strategic activities in areas of outbreak, epidemic and pandemic forecasting, surveillance, and data analytics within CDC and across the United States Government (USG); (3) guides the facilitation and coordination across federal, state, tribal, local, or territorial (STLT), and healthcare entities and engagement with relevant federal advisory committees with respect to disease modeling, forecasting, outbreak analytics, and critical data collections to support those efforts; (4) manages, directs, coordinates, and evaluates the activities of the Center; (5) defines goals and objectives for policy formation, scientific oversight, and guidance in program planning and development related to forecasting, surveillance, and analytics; (6) provides oversight for the evaluation of programmatic performance of forecasting, surveillance, and analytics; (7) manages intergovernmental and external affairs and cultivates strategic partnerships related to CFA activities; (8) ensures scientific quality, integrity, and clearance across the Center; (9) provides guidance and strategic oversight to the processes within the Center that access, collect, manage, analyze, and visualize data, including assistance for involvement with relevant federal advisory committees and other stakeholder groups; (10) collaborates and consults with other Centers, working groups, state and local health departments, other federal agencies, international partners, and other partners on CFA activities; (11) represents CFA and CDC

at professional and scientific meetings on topics consistent with CFA's mission; and (12) establishes and oversees the two offices within the Office of the Director.

Office of Policy and Communications (CD12)

(1) Provides leadership on issues management, budget formulation, and performance integration; (2) reviews, coordinates, and prepares legislation, briefing documents, Congressional testimony, and other legislative matters; (3) coordinates the development, review, and approval of federal regulations, Federal Register notices and announcements, Freedom of Information Act requests, General Accounting Office and Inspector General reports, and related activities for the Center; and (4) establishes and implements a communication strategy in support of CFA overarching goals and priorities.

Office of Management Services (CD13)

(1) Provides overall budgetary, employee relations, human capital management, logistics, and administrative support; (2) provides direction, strategy, analysis, and operational support in all aspects of human capital management, including workforce and career development and human resources operations; (3) manages operational budget processes, including planning, execution, and monitoring; (4) manages acquisition and grants management processes; (5) serves as point of contact on all matters concerning facilities management, property management, records management, equipment, travel, and space utilization and improvements; and (6) serves as coordinator of continuity of operations activities.

Inform Division (CDB)

(1) Communicates with expert disease modelers and emergency responders to provide public health policy decision support; (2) shares timely, actionable information with the federal government, STLT leaders, international partners, and the public; (3) works with and through public health partners to provide decision support and technical assistance; (4) develops, maintains, enhances data visualization capabilities to support CFA mission; (5) coordinates real-time monitoring efforts between CDC subject matter experts and USG interagency; and (6) maintains liaison with related Center staff, other officials of CDC, USG, and private sector partners.

Office of the Director (CDB1)

(1) Works with CFA OD to ensure spending plans and budgets are in line with overall division strategies and priorities; (2) ensures the CFA strategy is executed by the Inform Division and aligned with overall CDC goals; (3) develops execution strategies for outbreak communication, data visualization, and real-time monitoring efforts; (4) builds leadership at the division and team levels; (5) identifies and coordinates synergies between the division and federal, STLT, and international partners; (6) works directly with public health partners to provide decision support; (7) proposes resource priorities throughout the budget cycle; (8) works with CDC procurement office to facilitate procurement opportunities with industry partners; (9) ensures scientific quality, integrity, and clearance across the division; and (10) liaises with related Center staff, other officials of CDC, USG, and private sector partners.

Predict Division (CDD)

(1) Generates forecasts and analyses to support outbreak preparedness and response efforts; (2) provides real-time monitoring of disease outbreaks; (3) collaborates with federal, state, territorial, local, and tribal leaders and international partners on performing analytics to support decision-making; (4) assists with tabletop exercises to match policies and resources with forecasts; (5) supports the development of pandemic planning guidance; (6) develops scientific collaborations to harmonize analytic approaches and develop tools; (7) maintains analytic data sets and models during emergencies to address questions that arise with short latency; (8) identifies and gains access to sources of data relevant to outbreak analytics, forecasting, and modeling; and (9) builds, maintains, and improves modeling and forecasting platforms to be deployed during public health emergencies, including public-facing forecasts.

Office of the Director (CDD1)

(1) Works with CFA Office of the Director to ensure spending plans and budgets are in line with overall division strategies and priorities; (2) ensures the CFA strategy is executed by the Predict Division and aligned with overall CDC goals; (3) develops execution strategies for pandemic forecasting, surveillance, and outbreak response; (4) builds leadership at the division and team levels; (5) evaluates the strategies, focus, and prioritization of the division; (6)

identifies and coordinates synergies between the division and federal, STLT, and international partners; (7) facilitates tabletop exercises; (8) proposes resource priorities throughout the budget cycle; (9) works with CDC procurement office to facilitate procurement opportunities with industry partners; (10) ensures scientific quality, integrity, and clearance across the division; and (11) oversees the development and successful deployment of modeling and forecasting capabilities in emergency response situations.

Real Time Monitoring Branch (CDDB)

(1) Monitors outbreak events through established analytical tools and surveillance methods; (2) generates short-term forecasts of disease spread during an active outbreak; (3) utilizes data of previous outbreaks to monitor and forecast the behavior of potential and/or current outbreaks; and (4) generates multiple scenario models of potential/current outbreaks using established methodologies.

Analytics Response Branch (CDDC)

(1) Utilizes established analytical tools to help inform decision making for key partners during a potential and/or current outbreak; (2) Analyzes disease spread through existing data sources to identify key populations/settings at highest risk; (3) identifies potential economic impact of a forecasted/ ongoing outbreak event; (4) provides essential information to key partners in decisions surrounding community migration; (5) utilizes data analytics to inform decisions on potential variants of a pathogen; and (6) works with key partners to inform decisions on medical countermeasures during an active outbreak.

Technology and Innovation Division (CDE)

(1) Oversees the development, maintenance, and improvement of CFA's analytical architecture; (2) provides high-level support for CFA's strategic direction with respect to technology and innovative practices; (3) oversees product development for CFA and CFA's customers; (4) collaborates with other divisions within CFA to support research and development and provide technical assistance on an adhoc basis; (5) oversees the deployment of grants and cooperative agreements to support innovation within the Center.

Office of the Director (CDE1)

(1) Works with CFA OD to ensure spending plans and budgets are in line with overall division strategies and

priorities; (2) ensures that the CFA strategy is executed by the Technology & Innovation Division and aligned with overall CDC goals; (3) develops execution strategies for maintaining CFA's analytical architecture and supporting research and development across the division; (4) builds leadership at the division and branch levels; (5) coordinates with other divisions across CFA to support modeling, code development, and general research & development; (6) maintains strategic relationships with academic, private sector, and interagency partners; (7) works with CDC procurement office to facilitate procurement opportunities with industry partners; and (9) ensures scientific quality, integrity, and clearance across the division.

Technology Branch (CDEB)

(1) Establishes and maintains CFA analytical architecture; (2) devises information technology practices and procedures, and provides direction, innovation, planning, and evaluation for information technology systems, services, security, and resources for CFA; (3) monitors projects for effective focus on the analytical, informatics, data management, and statistical infrastructure to deliver timely, quality data, accurate analysis services, and dependable software products and systems to customers and partners: (4) develops, maintains, and operates analytics technology platforms; (5) engages in product development for CFA systems, enterprise systems, and analytical tools; (6) supports CFA in modeling and general code development, data engineering, and software development; (7) enables cloud environment architecture, development, deployment, and access; (8) supports CDC, USG efforts to maintain, enhance, and develop relevant systems that will address the CFA mission; and (9) maintains awareness of trends in technology and evaluates technology that would benefit the CFA mission.

Innovate Branch (CDEC)

(1) Supports research and development to improve outbreak forecasts and analyses; (2) collaborates with academic, private sector, and interagency partners; (3) creates translational tools, products, and enterprise enhancements to make analyses of pandemic data flexible, fast, and scalable for CFA customers including STLT authorities; (4) provides grants and cooperative agreements to support innovations in data analytics and modeling.

Delegations of Authority

All delegations and redelegations of authority made to officials and employees of affected organizational components will continue in them or their successors pending further redelegation, provided they are consistent with this reorganization.

(Authority: 44 U.S.C. 3101)

Xavier Becerra,

Secretary of Health and Human Services. [FR Doc. 2023–00151 Filed 1–6–23; 8:45 am]

BILLING CODE 4160-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; PHS–2023–1—NIH/NIAID 117 (Adjuvant Development for Vaccines for Infectious and Immune-Mediated Diseases).

Date: January 25, 2023.

Time: 9:00 a.m. to 5:30 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G43, Rockville, MD 20892 (Virtual Meeting).

Contact Person: Sandip Bhattacharyya, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G42, Rockville, MD 20852, (240) 292–0189, sandip.bhattacharyya@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: January 3, 2023.

Tveshia M. Roberson-Curtis,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023–00143 Filed 1–6–23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Interagency Coordinating Committee on the Validation of Alternative Methods Communities of Practice Webinar on Emerging Approaches for Anchoring Biological Relevance of New Approach Methodologies; Notice of Public Webinar; Registration Information

AGENCY: National Institutes of Health,

HHS.

ACTION: Notice.

SUMMARY: The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) announces a public webinar "Emerging Approaches for Anchoring Biological Relevance of New Approach Methodologies." The webinar is organized on behalf of ICCVAM by the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM). Interested persons may participate via the web meeting platform. Time will be allotted for questions from the audience. Information about the webinar and registration are available at https:// ntp.niehs.nih.gov/go/commprac-2023. DATES:

Webinar: January 30, 2023, 10:00 a.m. to approximately 12:00 noon EST.

Registration for Webinar: January 10, 2023, until 12:00 noon EST January 30, 2023. Registration to view the webinar is required.

ADDRESSES: Webinar web page: https://ntp.niehs.nih.gov/go/commprac-2023.

FOR FURTHER INFORMATION CONTACT: Dr. Nicole Kleinstreuer, Director, NICEATM, email: nicole.kleinstreuer@nih.gov, telephone: (984) 287–3150.

SUPPLEMENTARY INFORMATION:

Background: ICCVAM promotes the development and validation of toxicity testing methods that protect human health and the environment while replacing, reducing, or refining animal use. ICCVAM also provides guidance to test method developers and facilitates collaborations that promote the development of new test methods. To address these goals, ICCVAM will hold a Communities of Practice webinar on

"Emerging Approaches for Anchoring Biological Relevance of New Approach Methodologies."

"New approach methodologies" (NAMs) refers to approaches that can be used alone or in combination to provide information on chemical hazard and risk assessment without traditional animal tests. Traditional approaches to evaluating NAMs consider how well the results of chemical tests using NAMs correspond with the results of animal tests of the same chemicals. However, the usefulness of this approach is limited, especially when the animal results are variable, or the animal model does not adequately represent the species or effect of regulatory interest.

This webinar will discuss approaches to build confidence in NAMs that are based on evaluating the biological relevance of the NAM to the species of regulatory interest. Ongoing activities and key insights will be described in three presentations by speakers from the academic and private sector focusing on applications of small model organisms, organs-on-chips, and models of absorption, distribution, metabolism, and excretion. The preliminary agenda and additional information about presentations will be posted at https:// ntp.niehs.nih.gov/go/commprac-2023 as available.

Webinar and Registration: This webinar is open to the public with time scheduled for questions by participants following each presentation. Registration for the webinar is required. Registration will open on or before January 10, 2023 and remain open through 12:00 noon EST on January 30, 2023. Registration is available at https:// ntp.niehs.nih.gov/go/commprac-2023. Interested individuals are encouraged to visit this web page to stay abreast of the most current webinar information. Registrants will receive instructions on how to access and participate in the webinar in the email confirming their registration.

Background Information on ICCVAM and NICEATM: ICCVAM is an interagency committee composed of representatives from 17 federal regulatory and research agencies that require, use, generate, or disseminate toxicological and safety testing information. ICCVAM conducts technical evaluations of new, revised, and alternative safety testing methods and integrated testing strategies with regulatory applicability. ICCVAM also promotes the scientific validation and regulatory acceptance of testing methods that more accurately assess the safety and hazards of chemicals and products and replace, reduce, or refine animal use.